Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D.

Neuropsychopharmacology. 2010 Sep;35(10):2072-82. doi: 10.1038/npp.2010.79. Epub 2010 Jun 16.

2.
3.

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.

Schizophr Res. 2010 Feb;116(2-3):107-17. doi: 10.1016/j.schres.2009.10.026. Epub 2009 Dec 2.

PMID:
19959339
4.

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M.

Int J Neuropsychopharmacol. 2010 Jun;13(5):635-47. doi: 10.1017/S1461145709990988. Epub 2009 Nov 27.

PMID:
19941696
5.

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW.

Int Clin Psychopharmacol. 2010 Sep;25(5):247-56. doi: 10.1097/YIC.0b013e32833948fa.

PMID:
20389255
6.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
7.

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.

Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A. doi: 10.3371/CSRP.FUBO.022213.

PMID:
23446197
8.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS.

JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310. Erratum in: JAMA. 2014 Oct 8;312(14):1473.

9.

Paliperidone palmitate for schizophrenia.

Nussbaum AM, Stroup TS.

Cochrane Database Syst Rev. 2012 Jun 13;6:CD008296. doi: 10.1002/14651858.CD008296.pub2. Review.

PMID:
22696377
10.

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.

JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241.

PMID:
25820612
11.

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.

J Psychopharmacol. 2011 May;25(5):685-97. doi: 10.1177/0269881110372817. Epub 2010 Jul 8.

PMID:
20615933
12.

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.

Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J.

J Clin Psychopharmacol. 2010 Jun;30(3):235-44. doi: 10.1097/JCP.0b013e3181dd3103. Erratum in: J Clin Psychopharmacol. 2010 Aug;30(4):364.

PMID:
20473057
13.

Intramuscular paliperidone palmitate.

Hoy SM, Scott LJ, Keating GM.

CNS Drugs. 2010 Mar;24(3):227-44. doi: 10.2165/11203810-000000000-00000.

PMID:
20155997
14.

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):218-26. doi: 10.1016/j.pnpbp.2010.11.008. Epub 2010 Nov 16.

PMID:
21092748
15.

Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.

Sliwa JK, Bossie CA, Ma YW, Alphs L.

Schizophr Res. 2011 Oct;132(1):28-34. doi: 10.1016/j.schres.2011.06.016. Epub 2011 Jul 20.

PMID:
21775106
16.

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.

BMC Psychiatry. 2012 Mar 28;12:26. doi: 10.1186/1471-244X-12-26.

17.
18.

Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Carter NJ.

Drugs. 2012 May 28;72(8):1137-60. doi: 10.2165/11208640-000000000-00000.

PMID:
22571444
19.

Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.

Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.

Int Clin Psychopharmacol. 2014 Jan;29(1):45-55. doi: 10.1097/YIC.0000000000000006.

PMID:
24113628
20.

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1022-31. doi: 10.1016/j.pnpbp.2009.05.014. Epub 2009 May 28.

PMID:
19481579
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk